Stage 3 prostate cancer is a locally advanced form of disease, and is considered more aggressive than earlier stages. However, at this stage, the cancer has not spread to other parts of the body, meaning several treatment options are still available.
This guide provides a comprehensive overview of stage 3 prostate cancer, including symptoms, treatments, and prognosis to help you decide the best approach for your diagnosis.
What Is Stage 3 Prostate Cancer?
At Stage 3, prostate cancer is considered locally advanced. This means the cancer has not spread to distant parts of the body, but it shows higher-risk features such as tumour growth beyond the prostate capsule, significantly elevated PSA levels, or more aggressive tumour biology.
Under the TNM staging system¹, Stage 3 is defined by:
- Tumour: Most often T3 or T4, meaning the cancer has extended outside the prostate capsule and may involve nearby structures such as the seminal vesicles, bladder neck, rectum, or pelvic wall. In some cases, T1 or T2 tumours are classified as Stage 3 if other high-risk features are present.
- N0: No spread to nearby lymph nodes.
- M0: No spread to distant organs.
- PSA Level: PSA levels may vary. In some cases, a PSA level of 20 ng/mL or higher contributes to a Stage 3 classification.
- Grade Group: Stage 3 can include different Grade Groups. Very high-grade cancer, particularly Grade Group 5, can result in a Stage 3 classification even when spread is limited.
Stage 3 prostate cancer can vary significantly from one patient to another. The specific combination of tumour extent, PSA level, and Grade Group determines how the disease is classified.
For this reason, Stage 3 diagnoses are divided into substages 3A, 3B, and 3C to more precisely describe the extent and behaviour of the cancer. These substages are explained in the sections below.
How Stage 3 Prostate Cancer Is Diagnosed
A prostate cancer diagnosis usually begins with a PSA blood test and a digital rectal exam (DRE). While these tests alone do not confirm cancer, they may indicate the need for further evaluation.
If cancer is suspected, a prostate biopsy is performed to confirm the diagnosis. Tissue samples are examined under a microscope, and a Gleason score is assigned to reflect how aggressive the cancer appears. Imaging tests, such as prostate MRI, are used to determine whether the tumour has extended beyond the prostate capsule.
Doctors use this combined information when staging prostate cancer, and a Stage 3 diagnosis may be made when:
- PSA levels are 20 ng/mL or higher
- The tumour has grown beyond the prostate capsule
- Very high-grade cancer, such as Grade Group 5, is present
In all cases, Stage 3 requires no spread to lymph nodes or distant organs. If lymph node involvement or distant organ spread is detected, the disease is classified as Stage 4 prostate cancer.
Understanding Stage 3 Prostate Cancer Substages
| Substage | PSA Level | Grade Group | Tumour Involvement (T Stage) | Key Defining Feature |
| Stage 3A | ≥20 | 1–4 | T1–T2 (confined) | High PSA |
| Stage 3B | Any | 1–4 | T3–T4 (extends beyond capsule) | Tumour extension |
| Stage 3C | Any | 5 | Any T | High-grade biology |
Stage 3 prostate cancer can vary significantly between patients because it may be assigned based on tumour extent, prostate specific antigen (PSA) level, or cancer grade. These differences affect how advanced the disease appears and how it may behave.
Prostate Cancer Stage 3A
A Stage 3A diagnosis is assigned primarily based on PSA level. It applies when PSA levels are 20 ng/mL or higher, while the tumour remains confined to the prostate (T1 or T2, N0, M0).
At this substage, the cancer falls within Grade Groups 1 to 4, meaning it shows low to intermediate tumour aggressiveness. However, the significantly elevated PSA places the disease in the locally advanced category.
In Stage 3A, the defining feature is high PSA rather than visible tumour spread beyond the prostate.
Prostate Cancer Stage 3B
A Stage 3B diagnosis is assigned based on tumour extension beyond the prostate. It applies when the cancer has grown through the prostate capsule or into nearby structures such as the seminal vesicles (T3 or T4), but there is no spread to nearby lymph nodes (N0) or distant organs (M0).
At this substage, PSA levels can be at any value, and the cancer falls within Grade Groups 1 to 4, meaning tumour aggressiveness may range from low to high-intermediate.
In Stage 3B, the defining feature is visible tumour extension beyond the prostate rather than elevated PSA or high-grade tumour biology.
Prostate Cancer Stage 3C
A Stage 3C diagnosis is defined by tumour grade. It applies when the cancer is classified as Grade Group 5, corresponding to a Gleason score of 9 or 10, indicating highly aggressive tumour biology.
At this stage, PSA levels can be at any value, and the tumour may be confined to the prostate or have extended beyond it (any T stage). However, there is no spread to nearby lymph nodes (N0) or distant metastasis (M0).
In Stage 3C, the defining feature is high-grade tumour aggressiveness rather than PSA level or anatomical spread.
Stage 3 Prostate Cancer Symptoms
Although some patients with Stage 3 prostate cancer remain asymptomatic, this stage is more likely to produce noticeable symptoms than earlier stages. Most symptoms relate to urinary changes caused by tumour growth affecting urinary flow or involving nearby structures around the prostate.
Symptoms can include:
- Weak or reduced urine stream
- Increased urinary frequency
- Nocturia (waking at night to urinate)
- Difficulty initiating urination or a sensation of incomplete bladder emptying
- Pelvic or perineal discomfort
- Blood in the urine or semen
- Erectile dysfunction
It is important to note that symptoms alone do not determine the stage of prostate cancer. Some men with Stage 3 disease have minimal symptoms, while others may notice more pronounced urinary or pelvic changes.
Stage 3 Prostate Cancer Treatment Options
Active treatment is strongly recommended for Stage 3 prostate cancer. As a locally advanced stage, the disease is more likely to spread than prior stages. However, compared to other types of cancer, prostate cancer is generally slow to progress, which means you often have time to evaluate all available options.
The following are some of the most common approaches for treating stage 3 prostate cancer, including minimally invasive therapies offered at Vitus Private Clinic.
Irreversible Electroporation (IRE)
Irreversible Electroporation (IRE) is a non-thermal focal therapy that destroys cancer cells using short, high-voltage electrical pulses. Unlike treatments that rely on heat or freezing, IRE avoids thermal damage and helps preserve surrounding nerves, blood vessels, and connective tissue. This helps maintain urinary continence and erectile function.
The procedure uses thin needle electrodes inserted into the prostate under imaging guidance. Because it does not require surgical incisions, recovery is typically faster and hospital stays are shorter compared to radical prostatectomy.
IRE is most commonly used for localized prostate cancer. However, at Vitus Private Clinic, its application has expanded beyond early-stage disease.
With over 2,000 electroporation procedures performed, the clinic has developed refined manual electrode placement techniques that allow precise treatment of carefully selected cases of advanced localized and recurrent prostate cancer.
In appropriate Stage 3 cases, this approach can provide effective local tumour control while preserving surrounding structures, as demonstrated in the clinic’s published 2019 IRE cohort analysis.⁴
Electrochemotherapy
Electrochemotherapy (ECT) is another minimally invasive, non-thermal focal therapy that is only available for the treatment of prostate cancer at Vitus Private Clinic. This specialized approach combines reversible electroporation with low-dose chemotherapy to target and kill cancer cells.
The procedure starts with short electrical pulses administered to the treatment area. These pulses temporarily disturb the cancer cell membrane, allowing the chemotherapeutic drug to enter the cell more effectively.
Because it uses a much lower dose than traditional systemic chemotherapy, the risk of side effects such as fatigue, nausea, vomiting, and hair loss is significantly reduced. Most patients are released the morning after treatment and return to normal daily activities shortly after.
At Vitus Private Clinic, we use electrochemotherapy to treat locally advanced prostate cancer with complex anatomy or tumours located near sensitive areas where precision and tissue preservation are critical.
Clinical feasibility and early disease control outcomes were reported in Vitus Private Clinic’s published 2025 retrospective ECT cohort analysis.⁵
Non-Thermal Combination Therapies
Stage 3 prostate cancer often requires a combined treatment approach due to its complexity and proximity to sensitive areas. At Vitus Private Clinic, the IRECT procedure combines Irreversible Electroporation (IRE) with Electrochemotherapy (ECT).
IRECT establishes two treatment zones. The central IRE zone immediately destroys tumour cells with high-voltage electrical pulses. Surrounding this area is a reversible electroporation zone, where a low-dose chemotherapeutic agent enters cancer cells. This allows treatment of larger or irregular tumours while preserving nearby structures such as the bladder sphincter and rectum.
At Vitus Private Clinic, non-thermal focal therapies may also be combined with immunotherapy. Prostate cancer is typically considered a “cold” tumour, as it triggers limited immune recognition. However, non-thermal treatments preserve tumour antigens during cell destruction, which can improve immune visibility of the cancer.
Immunotherapy for prostate cancer can then support the body’s immune response, particularly in cases where microscopic disease may remain beyond the primary treatment zone.
For Stage 3 prostate cancer, where tumour extension and higher-risk features increase the likelihood of microscopic spread, this combined approach can play an important role in comprehensive disease management.
Call us now on +49 (0)177 23 82 863 or get in touch using the contact form
Radiation and Hormone Therapy
For many patients with Stage 3 prostate cancer, the current standard treatment is external beam radiation therapy (EBRT) combined with long-term androgen deprivation therapy (ADT).² Large clinical trials have shown that this combination improves cancer control and overall survival in men with locally advanced disease.
Treatment usually begins with hormone therapy to lower testosterone, which prostate cancer cells depend on for growth. ADT reduces prostate volume by about 20% on average, which improves radiation targeting and treatment accuracy.
External beam radiation therapy then delivers focused high-energy beams to destroy cancer cells in and around the prostate. However, combining radiation with long-term ADT increases the risk of side effects such as fatigue, hot flashes, reduced libido, and erectile dysfunction.
Radical Prostatectomy
Radical prostatectomy involves surgical removal of the entire prostate gland and a small margin of surrounding tissue. Although used less often than radiation-based approaches in Stage 3 disease, surgery may be considered for selected patients, especially when the tumour appears confined to or only slightly beyond the prostate capsule.
In some Stage 3 cases, prostatectomy is part of a multimodal treatment strategy, meaning additional radiation therapy or hormone therapy may be recommended after surgery to improve cancer control.
When the tumour has clearly invaded surrounding structures such as the bladder neck or rectum, surgery alone is unlikely to provide adequate disease control, and combined treatment approaches are typically recommended.
Active Surveillance
Active surveillance is uncommon in Stage 3 prostate cancer but may be considered in carefully selected patients, particularly those with lower-risk features or significant other health conditions.
Rather than immediate treatment, active surveillance involves close monitoring with regular PSA testing, imaging, and clinical evaluation. Treatment is initiated if there are signs that the cancer is progressing.
Because Stage 3 disease carries a higher risk of spread, this approach is typically reserved for patients where the risks of aggressive treatment outweigh the potential benefits.
Stage 3 Prostate Cancer Prognosis and Survival Rates
Stage 3 prostate cancer is considered locally advanced but remains highly treatable. According to U.S. National Cancer Institute data, the 5-year relative survival rate for regional prostate cancer, which includes Stage 3 disease, is approximately 99%.³
Although survival rates are high, Stage 3 disease carries a greater risk of recurrence than earlier stages. This is because the tumour may extend beyond the prostate capsule or display more aggressive biological features.
While no distant metastases are detected at the time of diagnosis, microscopic cancer cells can sometimes exist beyond the primary tumour site. For this reason, treatment strategies often focus not only on controlling the visible tumour, but also on reducing the risk of future progression.
Long-term outcomes vary depending on cancer substage, PSA level, Gleason score, and the treatment approach used.
With appropriate therapy and structured follow-up, many men with Stage 3 prostate cancer live long lives and maintain good quality of life.
Stage 3 Prostate Cancer Prognosis and Survival Rates
A Stage 3 prostate cancer diagnosis can feel overwhelming, but it does not mean you are without options. Many patients respond well to treatment and continue to live full, active lives with proper medical care and follow-up.
While therapy may be more complex than in earlier stages, advances in treatment have significantly improved outcomes and quality of life. Taking the time to understand your options and working with an experienced care team can make the path forward clearer.
If you would like to discuss your diagnosis or explore personalized treatment strategies, contact the team at Vitus Private Clinic for further guidance.
Frequently Asked Questions
Yes, Stage 3 prostate cancer can be considered curable. Many patients achieve long-term remission with appropriate treatment. However, because the cancer has extended beyond the prostate capsule or has higher-risk features, the likelihood of cure varies based on PSA level, Gleason score, and response to therapy.
Stage 3 prostate cancer may not cause noticeable symptoms, especially in early progression. When symptoms occur, they can include urinary difficulty, weak urine flow, pelvic discomfort, or blood in the urine or semen. Some patients are diagnosed based on elevated PSA levels before symptoms develop.
At diagnosis, Stage 3 prostate cancer has not spread to distant organs. However, because the tumour may extend beyond the prostate capsule, there is a higher risk of future spread compared to earlier stages. This is why timely treatment and structured follow-up are important.
Stage 3A is typically defined by a PSA level of 20 ng/mL or higher while the tumour remains confined to the prostate. Stage 3B involves tumour extension through the prostate capsule into nearby tissues. Stage 3C refers to cancer with a higher Grade Group (more aggressive cellular features), regardless of PSA level.
Treatment often includes radiation therapy combined with hormone therapy, surgery in selected cases, or specialized focal approaches in experienced centers. Because Stage 3 disease carries a higher risk of recurrence, combination strategies are commonly considered. The best approach depends on tumour characteristics and overall health.
Yes, recurrence is possible in Stage 3 prostate cancer. The risk is higher than in earlier stages because the tumour may have extended beyond the prostate. Regular PSA testing and follow-up care are essential to detect recurrence early and guide further treatment if needed.
- American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Current version. Available at: https://www.nccn.org. Accessed March 2026.
- National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. Available at: https://seer.cancer.gov/statfacts/html/prost.html. Accessed March 2026.
- Guenther E, Klein N, Zapf S, et al. Prostate cancer treatment with Irreversible Electroporation (IRE): safety, efficacy and clinical experience in 471 treatments. PLoS One. 2019;14(4):e0215093. Published 2019 Apr 15. doi:10.1371/journal.pone.0215093.
- Stevanovic M, Heringer M, Hjouj M, Zanasi A, Terlizzi F, Stehling MK. Prostate cancer treatment with electrochemotherapy (ECT): safety, efficacy and clinical experience in 144 patients. Radiol Oncol. 2025;59(4):597–606. Published 2025 Dec 16. doi:10.2478/raon-2025-0061.